ABSTRACT
Background: Glanzmann's Thrombasthenia [GT] is a rare inherited blood clotting [coagulation] disorder characterized by the impaired function of specialized cells [platelets] which are essential for proper blood clotting
Objectives: The present study aimed to assess the management steps of epistaxis in children with GM disease and assess the clinical outcome and the success rate or field of management
Methods: Data was taken via scanning all the patients' files in ENT clinic and 4 children with GM were identified as receiving therapy. Furthermore, data collected from each file were primary complaint needing a duration of hospitalization, intensive care unit [ICU] admission, coagulation management, hematologic results, medical therapy administration, blood products transfusion and the surgical intervention performed
Results: With a total of 25 hospital presentations, the highest percentage of the present symptoms was for epistaxis with 68% [17], then 16% [4] for gingival bleeding and 8% for each of menorrhagia and hematemesis
Conclusion and recommendation: Our study carried out the most effective technique that control epistaxis is Fresh Frozen [FFP] Plasma. The epistaxis in GT should be concern as sever threating life condition and should be managed with effective treatment
ABSTRACT
Background: asthma is the most common chronic illness that affects children. It is described by chronic airway inflammation, remodeling of the airway wall, and airway hyper-responsiveness to non-specific spasms in response to stimuli causing a reversible airflow obstruction. Leukotrienes are one of the primary chemical mediators of inflammation in asthmatic airway, therefore leukotriene modifiers are an important class of drug for treating asthma
Methodology: we conducted this review using a comprehensive search of MEDLINE, PubMed, and EMBASE, January 1981, through February 2017. The following search terms were used: asthma pathophysiology, chemokines, leukotriene, and leukotriene modifiers, Montelukast in asthma management
Aim: our aim was to understand in depth the pathophysiology of pediatric asthma, and to study the effect of leukotriene modifiers in asthma management
Conclusion: for management of pediatric asthma, the leukotriene modifiers play a key role. New studies have shown that they could help in reducing dose and dependency on inhaled corticosteroid for maintenance, and decrease the need of systemic steroids in exacerbation. Leukotriene modifiers can have a positive impact on future asthma management and requires more studies to be done in this subject